Hiroshi Sootome

A cell-based screening method for specifically detecting kinase activity

M. Suda, Tsuyoshi Ishii, Hiroshi Sootome, 2008, Analytical and bioanalytical chemistry.

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

P. Majumder, Hiroshi Sootome, H. Hirai, 2010, Molecular Cancer Therapeutics.

Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

Hiroshi Sootome, Kimihiro Ito, H. Hirai, 2020, Cancer Research.

Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo: Preclinical Studies as Guidance for Clinical Development and Trial Design

Hiroshi Sootome, H. Hirai, N. Masuko, 2020, Molecular Cancer Therapeutics.

Abstract 1117: Acquired resistance to ATP-competitive and irreversible FGFR inhibitors (FGFRi's): A library-based approach

Masanori Kato, Hiroshi Sootome, H. Hirai, 2021, Experimental and Molecular Therapeutics.